Naoki Hirota
YOU?
Author Swipe
View article: Brexpiprazole's impacts on patients and caregivers in agitation in Alzheimer's dementia
Brexpiprazole's impacts on patients and caregivers in agitation in Alzheimer's dementia Open
INTRODUCTION We evaluated the impacts of brexpiprazole treatment on patient neuropsychiatric symptoms and caregiver distress in Japanese patients with agitation in Alzheimer's dementia (AAD). METHODS In a phase 2/3 multicenter, double‐blin…
View article: Long-term safety and tolerability of brexpiprazole for Japanese patients with agitation in Alzheimer's disease dementia: A multicenter, open-label study
Long-term safety and tolerability of brexpiprazole for Japanese patients with agitation in Alzheimer's disease dementia: A multicenter, open-label study Open
Background The long-term safety and efficacy of brexpiprazole in Asian patients with agitation associated with dementia due to Alzheimer's disease are unknown. Objectives To evaluate the safety of 14-week treatment with brexpiprazole 1 or …
View article: Brexpiprazole treatment for agitation in Alzheimer's dementia: A randomized study
Brexpiprazole treatment for agitation in Alzheimer's dementia: A randomized study Open
INTRODUCTION We evaluated the efficacy and safety of brexpiprazole for the treatment of agitation in Alzheimer's dementia (AAD) in Japanese patients. METHODS This was a phase 2/3 multicenter, randomized, double‐blind, placebo‐controlled, p…